CPHI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Login
View profile
Log out
Welcome back

Click below to sign in and see leads, RFIs or statistics

Sign in

Sign out
- Search Impressions
  
  3 287
- Page views
  
  324
- Request for information
  
  54
Subscribe

Polpharma Biologics

About Polpharma Biologics

Polpharma Biologics is an international biotechnology company with integrated operations in the European Union (EU), developing and manufacturing biosimilar medicines. Using patented solutions and state-of-the-art platform technologies, we develop biosimilar products to treat a range of conditions in major therapeutic areas.

Certifications

FDA
GMP
Other

Sales Markets

Europe - EU countries
Europe - non EU (e.g. UK, Russia, ex-CIS countries)
North America (USA, Canada)

Categories

Polpharma Biologics

PL
2021

On CPHI since
3

Certificates
1000 - 4999

Employees

Compare

Add to favorites Added to favorites

Company types

Biopharmaceutical company

Generics/Biosimilars Manufacturer

Primary activities

Biopharmaceutical

Contact info

+48 58 770 95 59
Website
Trzy Lipy 3 Building A, Gdansk Science & Technology Park, 80-172, Gdansk, Poland

Meet us at

CPHI Frankfurt 2025

Messe, Frankfurt

28 Oct 2025 - 30 Oct 2025

View Exhibitor Profile

Products from Polpharma Biologics (1)

Product Pipeline

Polpharma Biologics has its own pipeline of biosimilars for out-licensing.
We are focused on advancing and expanding our product portfolio to increase patient access to these much-needed therapies and are open to partnering with other organizations to co-develop or commercialize our biosimilars.

Compare

Polpharma Biologics Resources (4)

News Polpharma Biologics’ investigational biosimilar shows PK/PD comparability to inflammatory bowel disease blockbuster Entyvio®

Polpharma Biologics, announced topline results demonstrating the pharmacokinetic (PK) and pharmacodynamic (PD) comparability of its biosimilar candidate PB016 to its reference drug, Entyvio®* (vedolizumab).

6 Sep 2024
Brochure Company Brochure

We care about creating quality biologics with passion!
News Polpharma Biologics announces approval of Europe’s first and only biosimilar for multiple sclerosis - Tyruko® (natalizumab)

Polpharma Biologics announced that the European Commission (EC) has approved Tyruko® (natalizumab) as the first and only biosimilar for relapsing forms of multiple sclerosis (MS) in Europe. Tyruko® was developed by Polpharma Biologics and will be commercialized by its collaboration partner Sandoz.

6 Sep 2024
News Polpharma Biologics announces FDA approval of Tyruko®

Polpharma Biologics, announced that the FDA is the first regulatory body worldwide to approve the use of Tyruko® (natalizumab-sztn) - a new biosimilar for the treatment of relapsing forms of multiple sclerosis (MS). Approval of Tyruko® by the European Medicines Agency is also expected imminently.

11 Sep 2023